Trial · NCT02322216
Olopatadine Hydrochloride Ophthalmic Solution Study in Chinese Subjects
NCT02322216, Phase 3, Completed, Alcon Research; results first posted 2016-10-12
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Olopatadine Hydrochloride Ophthalmic Solution Study in Chinese Subjects. Trials, record NCT02322216. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02322216
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Olopatadine Hydrochloride Ophthalmic Solution Study in Chinese Subjects
- NCT number
- NCT02322216
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 383 participants, actual
- Lead sponsor
- Alcon Research
- Conditions
- Allergic Conjunctivitis
- Interventions
- Olopatadine Hydrochloride Ophthalmic Solution 0.2%, Olopatadine Hydrochloride Ophthalmic Solution 0.1%, Olopatadine 0.2% Vehicle
- First posted
- 2014-12-23
- Last updated
- 2017-11-17
- Other registries' IDs
- eudract:2016-004317-27
- Results first posted
- 2016-10-12
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change From Baseline in Worst Ocular Itching Score During the 24 Hours Prior at Day 14 | Baseline, Day 14 | Severity of ocular itching was evaluated as the worst score observed in the past 24 hours prior to each study visit. Ocular itching was assessed by the participant on a scale from 0-4, where 0=None and 4=Incapacitating itch. One eye (study eye) contributed to the analysis. |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change From Baseline in Worst Ocular Itching Score During the 24 Hours Prior at Day 14 | Baseline, Day 14 | Per Protocol Set with non-missing data | units on a scale | MEAN |
Source ClinicalTrials.gov
Results by group2
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline in Worst Ocular Itching Score During the 24 Hours Prior at Day 14 | PATADAY | -2.57 | Standard Error 0.090 | units on a scale | |
| Change From Baseline in Worst Ocular Itching Score During the 24 Hours Prior at Day 14 | PATANOL | -2.62 | Standard Error 0.092 | units on a scale |
Source ClinicalTrials.gov
Participant flow10
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | PATADAY | 126 | |
| Overall Study | STARTED | PATANOL | 127 | |
| Overall Study | Treated (Safety Set) | PATADAY | 126 | |
| Overall Study | Treated (Safety Set) | PATANOL | 126 | |
| Overall Study | Per Protocol Set (PPS) | PATADAY | 123 | |
| Overall Study | Per Protocol Set (PPS) | PATANOL | 122 | |
| Overall Study | COMPLETED | PATADAY | 124 | |
| Overall Study | COMPLETED | PATANOL | 123 | |
| Overall Study | NOT COMPLETED | PATADAY | 2 | |
| Overall Study | NOT COMPLETED | PATANOL | 4 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals9
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Pre-treatment | ||
| Total, all-cause mortality | PATADAY | ||
| Total, all-cause mortality | PATANOL | ||
| Total, other adverse events | Pre-treatment | 0 | 383 |
| Total, other adverse events | PATADAY | 0 | 126 |
| Total, other adverse events | PATANOL | 0 | 126 |
| Total, serious adverse events | Pre-treatment | 0 | 383 |
| Total, serious adverse events | PATADAY | 0 | 126 |
| Total, serious adverse events | PATANOL | 0 | 126 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02322216
GET https://conductscience.org/api/trials/v1/NCT02322216/registered